Clinical Trial Update: Vestipitant 28-day Tolerance Study [Phase 2]

View source ↗

Summary

GlaxoSmithKline completed a Phase 2 28-day tolerance study evaluating Vestipitant for sleep disorders.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sleep Disorders

Drugs mentioned

• Vestipitant (vestipitant)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Sleep Disorders | Phase 2 | Status: COMPLETED